Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00721513 · OUTCOME

MD Anderson Dysphagia Inventory

Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer · Source last updated 2020-04-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Score on a scale
Interval / dispersion
Standard Deviation
Time frame
Baseline, pre-radiation therapy and post-radiation therapy, up to 2 years

What was measured

The MD Anderson Dysphasia Inventory (MDADI) is a survey specifically designed to assess dysphasia. It contains 20 questions directly addressing the swallowing function and several other general questions. The questionnaire asks for participants views about their swallowing ability at baseline, pre-radiation therapy and post-radiation therapy. All questions except for E7 and F2: Strongly Agree = 1 point, Agree = 2 points, No Opinion = 3 points, Disagree = 4 points, Strongly Disagree. E7 and F2: Strongly agree = 5 points, Agree = 4 points, no opinion = 3 points, disagree = 2 points, strongly disagree = 1 point. Scores range from 20 (extremely low-functioning) to 100 (high-functioning).

Analysis population: Data was not collected on all participants

Groups in this outcome

TPFChemotherapy + Concomitant Cetuximab & RT

Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab \& Radiation Therapy cetuximab cisplatin docetaxel fluorouracil computed tomography positron emission tomography quality-of-life assessment 3-dimensional conformal radiation therapy intensity-modulated radiation therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT10

Reported measurements

Baseline Global Score

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT10
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT56.0032.39Not reportedNot reportedNot reported
Baseline Emotion Score

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT9
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT71.4816.68Not reportedNot reportedNot reported
Baseline Function Score

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT9
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT75.5620.34Not reportedNot reportedNot reported
Baseline Physical Score

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT10
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT68.0022.94Not reportedNot reportedNot reported
Pre-RT Global Score

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT5
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT88.0026.83Not reportedNot reportedNot reported
Pre-RT Emotion Score

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT5
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT83.076.35Not reportedNot reportedNot reported
Pre-RT Function Score

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT5
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT76.809.96Not reportedNot reportedNot reported
Pre-RT Physical Score

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT5
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT86.0019.89Not reportedNot reportedNot reported
Post-RT Global Score

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT8
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT62.5036.15Not reportedNot reportedNot reported
Post-RT Emotion Score

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT8
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT67.0817.59Not reportedNot reportedNot reported
Post-RT Function Score

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT7
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT58.2926.62Not reportedNot reportedNot reported
Post-RT Physical Score

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT8
Values in Score on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT67.8126.47Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        32.39
        value
        56.00
    denoms
    1. counts
      1. group Id
        OG000
        value
        10
      units
      Participants
    title
    Baseline Global Score
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        16.68
        value
        71.48
    denoms
    1. counts
      1. group Id
        OG000
        value
        9
      units
      Participants
    title
    Baseline Emotion Score
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        20.34
        value
        75.56
    denoms
    1. counts
      1. group Id
        OG000
        value
        9
      units
      Participants
    title
    Baseline Function Score
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        22.94
        value
        68.00
    denoms
    1. counts
      1. group Id
        OG000
        value
        10
      units
      Participants
    title
    Baseline Physical Score
  5. categories
    1. measurements
      1. group Id
        OG000
        spread
        26.83
        value
        88.00
    denoms
    1. counts
      1. group Id
        OG000
        value
        5
      units
      Participants
    title
    Pre-RT Global Score
  6. categories
    1. measurements
      1. group Id
        OG000
        spread
        6.35
        value
        83.07
    denoms
    1. counts
      1. group Id
        OG000
        value
        5
      units
      Participants
    title
    Pre-RT Emotion Score
  7. categories
    1. measurements
      1. group Id
        OG000
        spread
        9.96
        value
        76.80
    denoms
    1. counts
      1. group Id
        OG000
        value
        5
      units
      Participants
    title
    Pre-RT Function Score
  8. categories
    1. measurements
      1. group Id
        OG000
        spread
        19.89
        value
        86.00
    denoms
    1. counts
      1. group Id
        OG000
        value
        5
      units
      Participants
    title
    Pre-RT Physical Score
  9. categories
    1. measurements
      1. group Id
        OG000
        spread
        36.15
        value
        62.50
    denoms
    1. counts
      1. group Id
        OG000
        value
        8
      units
      Participants
    title
    Post-RT Global Score
  10. categories
    1. measurements
      1. group Id
        OG000
        spread
        17.59
        value
        67.08
    denoms
    1. counts
      1. group Id
        OG000
        value
        8
      units
      Participants
    title
    Post-RT Emotion Score
  11. categories
    1. measurements
      1. group Id
        OG000
        spread
        26.62
        value
        58.29
    denoms
    1. counts
      1. group Id
        OG000
        value
        7
      units
      Participants
    title
    Post-RT Function Score
  12. categories
    1. measurements
      1. group Id
        OG000
        spread
        26.47
        value
        67.81
    denoms
    1. counts
      1. group Id
        OG000
        value
        8
      units
      Participants
    title
    Post-RT Physical Score
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
The MD Anderson Dysphasia Inventory (MDADI) is a survey specifically designed to assess dysphasia. It contains 20 questions directly addressing the swallowing function and several other general questions. The questionnaire asks for participants views about their swallowing ability at baseline, pre-radiation therapy and post-radiation therapy. All questions except for E7 and F2: Strongly Agree = 1 point, Agree = 2 points, No Opinion = 3 points, Disagree = 4 points, Strongly Disagree. E7 and F2: Strongly agree = 5 points, Agree = 4 points, no opinion = 3 points, disagree = 2 points, strongly disagree = 1 point. Scores range from 20 (extremely low-functioning) to 100 (high-functioning).
dispersion Type
Standard Deviation
groups
  1. description
    Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab \& Radiation Therapy cetuximab cisplatin docetaxel fluorouracil computed tomography positron emission tomography quality-of-life assessment 3-dimensional conformal radiation therapy intensity-modulated radiation therapy
    id
    OG000
    title
    TPFChemotherapy + Concomitant Cetuximab & RT
param Type
MEAN
population Description
Data was not collected on all participants
reporting Status
POSTED
time Frame
Baseline, pre-radiation therapy and post-radiation therapy, up to 2 years
title
MD Anderson Dysphagia Inventory
type
SECONDARY
unit Of Measure
Score on a scale

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice